# Ying Wei ch

> Ying Wei ch is a Series A investor at CDH Investments backing Medical and Consumer. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CDH Investments](https://shizune.co/investors/profile/cdh-investments)
- Total investments: 3
- Last investment: Dec 2023
- Lead investor: 33%
- Last updated: Aug 2026

Ying Wei ch is a Series A investor at CDH Investments focused on Medical and Consumer. Prior to joining CDH in 2009, Ying spent 18 years of his career with China Resources (Holding) Ltd., a China state-owned “Blue Chip” company listed in Hong Kong, where he successively took the positions of Director, Vice President and Operations Director of Hong Kong China Resources Textile Group. After leaving China Resources in 2007, Ying spent 2years at China Water Group (0855.HK) as Vice President in charge of investment, M&A and financial control of the Group. Prior to joining CDH, Ying was the CEO and Executive Director of China Botanic Development (Holding) Ltd. (2349.HK). Ying received his Bachelor of Management in Accounting from Huangzhou Institute of Commerce and his M.B.A. from the University of San Francisco. Ying is a qualified Chinese CPA and also a non-practitioner member of Shenzhen CPA Association.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Consumer | 1 | 33% |
| Robotics | 1 | 33% |
| Biopharma | 1 | 33% |
| Biotechnology | 1 | 33% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Corerain Technologies | Corerain Technologies provides high performance AI acceleration solutions to embedding frontend, edge and backend AI devices. |  | Series C | Dec 27, 2023 |  |
| Chuangjian Medical | Chuangjian Medical is a technological innovation company that focuses on the creation, sale, and research & development of novel protein- and nucleic acid-based medicines. | $29.7M | Series A | Aug 10, 2022 |  |
| Yunji Technology | Yunji Technology is a Chinese robot company that builds a commercial service robot capable of delivering goods. | $120M | Series B | Apr 24, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Beijing Huafang Investment](https://shizune.co/investors/profile/beijing-huafang-investment) — VC Fund, 1 deal together
- [Bell Tower Financial Holdings](https://shizune.co/investors/profile/bell-tower-financial-holdings) — VC Fund, 1 deal together
- [China Unicom](https://shizune.co/investors/profile/china-unicom) — VC Fund, 1 deal together
- [Holley Group](https://shizune.co/investors/profile/holley-group) — VC Fund, 1 deal together
- [Huaxing Growth Capital](https://shizune.co/investors/profile/huaxing-growth-capital) — VC Fund, 1 deal together
- [ProCapital](https://shizune.co/investors/profile/procapital-d6ea) — VC Fund, 1 deal together

## About CDH Investments

VC Fund · Kowloon City, Hong Kong

CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.

5 contacts available at CDH Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Steven Wang | Partner | https://shizune.co/investors/profile/steven-wang |
| Vivian Chen | Investment Team | https://shizune.co/investors/profile/vivian-chen-2 |
| Ying Wei ch | Managing Director and Operating Partner | https://shizune.co/investors/profile/ying-wei-ch |
| Zhang Haifeng | Partner | https://shizune.co/investors/profile/zhang-haifeng |
| Andy Xi | Partner | https://shizune.co/investors/profile/andy-xi |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ying Wei ch invest in?

Ying Wei ch invests primarily in Medical, Consumer and Robotics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ying Wei ch last invest?

The most recent investment recorded for Ying Wei ch closed in Dec 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co